---
layout: default
title: Etanercept
description: "Etanercept çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æ¨¡å‹é æ¸¬ç­‰ç´š L5ï¼ŒåŒ…å« 6 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: åƒ…æ¨¡å‹é æ¸¬ (L5)
nav_order: 67
evidence_level: L1
indication_count: 6
---

# Etanercept

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L5</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>6</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Etanercept è—¥å¸«è©•ä¼°ç­†è¨˜

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Etanercept å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Etanercept æ˜¯ä¸€ç¨® TNF-alpha æŠ‘åˆ¶åŠ‘ï¼ŒTxGNN é æ¸¬å…¶å¯èƒ½ç”¨æ–¼å¤šç¨®ç¥ç¶“é€€åŒ–æ€§ç–¾ç—…ï¼Œä½†ç›®å‰ç¼ºä¹è‡¨åºŠè©¦é©—æ”¯æŒã€‚
</p>


## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| è—¥ç‰©åç¨± | Etanercept (æ©åš) |
| DrugBank ID | DB00005 |
| å°ç£å•†å“å | çˆ¾ç‘æ˜“æ³¨å°„æ¶² |
| åŸæ ¸å‡†é©æ‡‰ç—‡ | é¡é¢¨æ¿•æ€§é—œç¯€ç‚ã€ä¹¾ç™¬æ€§é—œç¯€ç‚ã€åƒµç›´æ€§è„Šæ¤ç‚ã€ä¸­é‡åº¦ä¹¾ç™¬ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | ankylosing spondylitisã€rheumatoid vasculitisã€hypermobility of coccyxã€inflammatory spondylopathyã€spondyloarthropathy, susceptibility toã€Kummell disease |
| æœ€é«˜é æ¸¬åˆ†æ•¸ | 0.9986 (primary progressive multiple sclerosis) |
| è­‰æ“šç­‰ç´š | L5 (åƒ…é æ¸¬) |



## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. rheumatoid vasculitis</span>
<span class="evidence-badge evidence-L2">L2</span>
<span class="prediction-score">99.71%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content">

<h3>ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ</h3>

<p>Etanercept é€éæŠ‘åˆ¶ TNF-alpha ç™¼æ®å…ç–«èª¿ç¯€ä½œç”¨ã€‚TNF-alpha åœ¨ç¥ç¶“é€€åŒ–æ€§ç–¾ç—…ä¸­çš„è§’è‰²å·²è¢«å»£æ³›ç ”ç©¶ï¼š</p>

<ol>
<li><strong>ç™¼ç‚æ©Ÿè½‰é—œè¯</strong>ï¼šTNF-alpha åƒèˆ‡ä¸­æ¨ç¥ç¶“ç³»çµ±çš„ç™¼ç‚åæ‡‰ï¼Œè€Œç¥ç¶“ç™¼ç‚æ˜¯å¤šç™¼æ€§ç¡¬åŒ–ç—‡å’Œè¦–ç¥ç¶“è„Šé«“ç‚çš„é‡è¦ç—…ç†æ©Ÿåˆ¶</li>
<li><strong>è¡€è…¦å±éšœé€šé€æ€§</strong>ï¼šTNF-alpha å¯å¢åŠ è¡€è…¦å±éšœé€šé€æ€§ï¼Œç†è«–ä¸ŠæŠ‘åˆ¶ TNF-alpha å¯èƒ½æ¸›å°‘ç¥ç¶“æå‚·</li>
<li><strong>å…ç–«èª¿ç¯€é‡ç–Š</strong>ï¼šEtanercept å·²æ ¸å‡†ç”¨æ–¼å¤šç¨®è‡ªé«”å…ç–«ç–¾ç—…ï¼Œé€™äº›ç–¾ç—…èˆ‡ç¥ç¶“è‡ªé«”å…ç–«ç–¾ç—…æœ‰éƒ¨åˆ†æ©Ÿè½‰é‡ç–Š</li>

</ol>
<p>ç„¶è€Œéœ€æ³¨æ„ï¼šEtanercept ç‚ºå¤§åˆ†å­ç”Ÿç‰©è£½åŠ‘ï¼Œé›£ä»¥ç©¿é€è¡€è…¦å±éšœï¼Œé€™å°ä¸­æ¨ç¥ç¶“ç³»çµ±ç–¾ç—…çš„æ²»ç™‚æ§‹æˆæŒ‘æˆ°ã€‚</p>

<h3>è‡¨åºŠè©¦é©—</h3>

<p>ç›®å‰åœ¨ ClinicalTrials.gov å’Œ ICTRP è³‡æ–™åº«ä¸­ï¼Œ<strong>æœªç™¼ç¾</strong> Etanercept ç”¨æ–¼ä»¥ä¸‹é æ¸¬é©æ‡‰ç—‡çš„è‡¨åºŠè©¦é©—ï¼š</p>
<ul>
<li>Primary progressive multiple sclerosis</li>
<li>Neuromyelitis optica</li>
<li>Amyotrophic lateral sclerosis</li>
<li>Huntington disease</li>

</ul>
<p><strong>è­‰æ“šç­‰ç´šï¼šL5 (åƒ…é æ¸¬)</strong></p>

<h3>ç›¸é—œæ–‡ç»</h3>

<p>PubMed æ–‡ç»æœå°‹çµæœï¼š</p>

<table>
<thead>
<tr>
<th>é æ¸¬é©æ‡‰ç—‡</th>
<th>ç›¸é—œæ–‡ç»æ•¸</th>
<th>é—œéµç™¼ç¾</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary progressive MS</td>
<td>0</td>
<td>ç„¡ç›´æ¥ç›¸é—œç ”ç©¶</td>
</tr>
<tr>
<td>Neuromyelitis optica</td>
<td>0</td>
<td>ç„¡ç›´æ¥ç›¸é—œç ”ç©¶</td>
</tr>
<tr>
<td>ALS</td>
<td>0</td>
<td>ç„¡ç›´æ¥ç›¸é—œç ”ç©¶</td>
</tr>
<tr>
<td>Huntington disease</td>
<td>0</td>
<td>ç„¡ç›´æ¥ç›¸é—œç ”ç©¶</td>
</tr>
</tbody>
</table>

<p>ç›®å‰ç¼ºä¹ç›´æ¥æ”¯æŒé€™äº›é æ¸¬çš„æ–‡ç»è­‰æ“šã€‚</p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. hypermobility of coccyx</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.63%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. inflammatory spondylopathy</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.57%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ50 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02509026" target="_blank">NCT02509026</a></td><td>PHASE4</td><td>COMPLETED</td><td>210</td><td>A MULTICENTER OPEN-LABEL STUDY OF ETANERCEPT WITHDRAWAL AND RETREATMENT IN SUBJE...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02376790" target="_blank">NCT02376790</a></td><td>PHASE3</td><td>COMPLETED</td><td>851</td><td>A Multicenter Double-Blind, Randomized Controlled Study of Etanercept and Methot...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03729674" target="_blank">NCT03729674</a></td><td>N/A</td><td>UNKNOWN</td><td>800</td><td>Comparative Effectiveness and Safety of Biosimilar and Legacy Drugs</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05164198" target="_blank">NCT05164198</a></td><td>PHASE4</td><td>UNKNOWN</td><td>448</td><td>Multicenter, Prospective Clinical Trial for Optimizing TNF Inhibitor Dose Adjust...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01934933" target="_blank">NCT01934933</a></td><td>PHASE4</td><td>COMPLETED</td><td>150</td><td>A Multi-center, Open Label, Random Clinical Trial of Etanercept and Celecoxib Al...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 45 é …è©¦é©—</em></p>

<h3>ç›¸é—œæ–‡ç»ï¼ˆ20 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/25438042/" target="_blank">25438042</a></td><td>2015</td><td>Article</td><td>Current medical rese</td><td>Etanercept and uveitis: friends or foes?</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/24980068/" target="_blank">24980068</a></td><td>2015</td><td>Article</td><td>Rheumatology interna</td><td>Etanercept biosimilars.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28940172/" target="_blank">28940172</a></td><td>2017</td><td>Article</td><td>BioDrugs : clinical </td><td>GP2015: An Etanercept Biosimilar.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/17072572/" target="_blank">17072572</a></td><td>2006</td><td>Article</td><td>Zeitschrift fur Rheu</td><td>[Spondylarthritides].</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28837372/" target="_blank">28837372</a></td><td>2018</td><td>Article</td><td>Modern rheumatology</td><td>Update upon efficacy and safety of etanercept for the treatm...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 15 ç¯‡æ–‡ç»</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. Kummell disease</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.55%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. polyarticular juvenile rheumatoid arthritis</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.50%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ8 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06654882" target="_blank">NCT06654882</a></td><td>PHASE3</td><td>NOT_YET_RECRUITING</td><td>400</td><td>Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthri...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01145352" target="_blank">NCT01145352</a></td><td>N/A</td><td>COMPLETED</td><td>113</td><td>Enbrel-JIA Use Results Survey [All-Case Surveillance]</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03780959" target="_blank">NCT03780959</a></td><td>PHASE2, PHASE3</td><td>COMPLETED</td><td>69</td><td>Safety, Population Pharmacokinetics, and Efficacy of Recombinant Human Tumor Nec...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03781375" target="_blank">NCT03781375</a></td><td>PHASE3</td><td>TERMINATED</td><td>25</td><td>A Phase III Double Blind Randomized Study Comparing Etanercept (Enbrel) Combined...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06413563" target="_blank">NCT06413563</a></td><td>N/A</td><td>NOT_YET_RECRUITING</td><td>75</td><td>Analysis of Peripheral Blood Lymphocytes in Patients With Juvenile Idiopathic Ar...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 3 é …è©¦é©—</em></p>

<h3>ç›¸é—œæ–‡ç»ï¼ˆ20 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28418334/" target="_blank">28418334</a></td><td>2017</td><td>Article</td><td>Balkan medical journ</td><td>Juvenile Idiopathic Arthritis.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/26233720/" target="_blank">26233720</a></td><td>2015</td><td>Article</td><td>Clinical rheumatolog</td><td>Enthesitis-related arthritis.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/40148850/" target="_blank">40148850</a></td><td>2025</td><td>Article</td><td>BMC pediatrics</td><td>Comparative efficacy and safety of etanercept and adalimumab...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/29781829/" target="_blank">29781829</a></td><td>2019</td><td>Article</td><td>Journal of clinical </td><td>Comparison of Adults With Polyarticular Juvenile Idiopathic ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/12641492/" target="_blank">12641492</a></td><td>2003</td><td>Article</td><td>BioDrugs : clinical </td><td>Spotlight on etanercept in rheumatoid arthritis, psoriatic a...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 15 ç¯‡æ–‡ç»</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. vertebral disease</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.16%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ6 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01258738" target="_blank">NCT01258738</a></td><td>PHASE3</td><td>COMPLETED</td><td>225</td><td>A Multicentre, 12 Week Double Blind Placebo Controlled Randomized Study Of Etane...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05115903" target="_blank">NCT05115903</a></td><td>PHASE4</td><td>UNKNOWN</td><td>15</td><td>A Prospective, Randomized Biologic Tapering Study of TNF Inhibitors in Axial Spo...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02809781" target="_blank">NCT02809781</a></td><td>PHASE2, PHASE3</td><td>UNKNOWN</td><td>250</td><td>Phase III Study of Human Bone Marrow-Derived Mesenchymal Stem Cells to Treat AS</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00413400" target="_blank">NCT00413400</a></td><td>NA</td><td>COMPLETED</td><td>40</td><td>Effects of Etanercept in Patients With the Metabolic Syndrome (II)</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01188655" target="_blank">NCT01188655</a></td><td>N/A</td><td>COMPLETED</td><td>89</td><td>Observational Non-Interventional Study With Enbrel in Patients With Ankylosing S...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 1 é …è©¦é©—</em></p>

<h3>ç›¸é—œæ–‡ç»ï¼ˆ20 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31969328/" target="_blank">31969328</a></td><td>2020</td><td>Article</td><td>Annals of the rheuma</td><td>EULAR recommendations for the management of rheumatoid arthr...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38503473/" target="_blank">38503473</a></td><td>2024</td><td>Article</td><td>Annals of the rheuma</td><td>Efficacy and safety of pharmacological treatment of psoriati...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/17072572/" target="_blank">17072572</a></td><td>2006</td><td>Article</td><td>Zeitschrift fur Rheu</td><td>[Spondylarthritides].</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28682112/" target="_blank">28682112</a></td><td>2017</td><td>Article</td><td>Expert opinion on bi</td><td>Etanercept for treating axial spondyloarthritis.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/35543102/" target="_blank">35543102</a></td><td>2023</td><td>Article</td><td>Scandinavian journal</td><td>Does a short course of etanercept influence disease progress...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 15 ç¯‡æ–‡ç»</em></p>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

| é …ç›® | å…§å®¹ |
|------|------|
| è¨±å¯è­‰å­—è™Ÿ | è¡›ç½²èŒç–«è¼¸å­—ç¬¬000876è™Ÿ |
| ä¸­æ–‡å“å | çˆ¾ç‘æ˜“æ³¨å°„æ¶² |
| è‹±æ–‡å“å | Enbrel Solution for Injection |
| è¨±å¯è­‰æŒæœ‰è€… | è¼ç‘å¤§è—¥å» è‚¡ä»½æœ‰é™å…¬å¸ |
| åŠ‘å‹ | æ³¨å°„åŠ‘ |
| æ ¸å‡†æ—¥æœŸ | 2012/03/26 |
| æœ‰æ•ˆæœŸé™ | 2027/03/26 |
| ç‹€æ…‹ | æœ‰æ•ˆ |

## å®‰å…¨æ€§è€ƒé‡

### å·²çŸ¥é¢¨éšª
- **æ„ŸæŸ“é¢¨éšªå¢åŠ **ï¼šåŒ…æ‹¬åš´é‡ç´°èŒã€ç—…æ¯’ã€çœŸèŒæ„ŸæŸ“
- **çµæ ¸ç—…å†æ´»åŒ–**ï¼šä½¿ç”¨å‰éœ€ç¯©æª¢æ½›ä¼æ€§çµæ ¸
- **æƒ¡æ€§è…«ç˜¤é¢¨éšª**ï¼šé•·æœŸä½¿ç”¨å¯èƒ½å¢åŠ æ·‹å·´ç˜¤é¢¨éšª
- **æ³¨å°„éƒ¨ä½åæ‡‰**ï¼šå¸¸è¦‹å±€éƒ¨åæ‡‰

### è—¥ç‰©äº¤äº’ä½œç”¨
æ ¹æ“š DDInter è³‡æ–™åº«ï¼ŒEtanercept èˆ‡ä»¥ä¸‹è—¥ç‰©æœ‰äº¤äº’ä½œç”¨ï¼š
- Anakinra (Major)ï¼šä¸å»ºè­°ä½µç”¨ï¼Œå¢åŠ åš´é‡æ„ŸæŸ“é¢¨éšª
- Abatacept (Major)ï¼šä¸å»ºè­°ä½µç”¨
- æ´»ç–«è‹—ï¼šç¦æ­¢ä½µç”¨

### ç‰¹æ®Šæ—ç¾¤
- **å­•å©¦**ï¼šC ç´šï¼Œæ¬Šè¡¡åˆ©å¼Šå¾Œä½¿ç”¨
- **å“ºä¹³**ï¼šå°‘é‡åˆ†æ³Œè‡³ä¹³æ±
- **è‚è…åŠŸèƒ½ä¸å…¨**ï¼šç„¡éœ€èª¿æ•´åŠ‘é‡

### è—¥ç‰©-è‰è—¥äº¤äº’ä½œç”¨ (DHI)

**ç´«éŒèŠ±** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šç´«éŒèŠ±å¯èƒ½èˆ‡å…ç–«èª¿ç¯€è—¥ç‰©ç”¢ç”Ÿäº¤äº’ä½œç”¨
- å»ºè­°ï¼šè¬¹æ…ä½¿ç”¨


## çµè«–èˆ‡ä¸‹ä¸€æ­¥

### æ•´é«”è©•ä¼°
æ­¤é æ¸¬ç›®å‰**ä¸å»ºè­°è‡¨åºŠæ‡‰ç”¨**ï¼ŒåŸå› å¦‚ä¸‹ï¼š
1. ç¼ºä¹ä»»ä½•è‡¨åºŠè©¦é©—æˆ–è§€å¯Ÿæ€§ç ”ç©¶æ”¯æŒ
2. Etanercept ç‚ºå¤§åˆ†å­è—¥ç‰©ï¼Œä¸­æ¨ç¥ç¶“ç³»çµ±æ»²é€æ€§å·®
3. éƒ¨åˆ†é æ¸¬é©æ‡‰ç—‡(å¦‚ MS)å¯¦éš›ä¸Šå¯èƒ½å›  TNF æŠ‘åˆ¶è€Œæƒ¡åŒ–

### å»ºè­°è¡Œå‹•
- [ ] éœ€è¦æ›´å¤šåŸºç¤ç ”ç©¶æ¢è¨ TNF-alpha æŠ‘åˆ¶åœ¨ç¥ç¶“é€€åŒ–æ€§ç–¾ç—…ä¸­çš„è§’è‰²
- [ ] è‹¥è¦é€²è¡Œè‡¨åºŠç ”ç©¶ï¼Œéœ€å…ˆè§£æ±ºè—¥ç‰©éé€è‡³ä¸­æ¨ç¥ç¶“ç³»çµ±çš„å•é¡Œ
- [ ] å¯†åˆ‡ç›£æ¸¬å·²ä½¿ç”¨ Etanercept æ‚£è€…æ˜¯å¦å‡ºç¾ç¥ç¶“ç³»çµ±ç—‡ç‹€

### é¢¨éšªç­‰ç´š
**é«˜é¢¨éšª** - ä¸å»ºè­°è¶…é©æ‡‰ç—‡ä½¿ç”¨

---

*å ±å‘Šç”Ÿæˆæ—¥æœŸï¼š2026-02-11*
*è³‡æ–™ä¾†æºï¼šTxGNN é æ¸¬ã€ClinicalTrials.govã€PubMedã€TFDA*


---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Homatropine Methylbromide]({{ "/drugs/homatropine_methylbromide/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Nitrofurantoin]({{ "/drugs/nitrofurantoin/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Urea]({{ "/drugs/urea/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Vigabatrin]({{ "/drugs/vigabatrin/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Bevacizumab]({{ "/drugs/bevacizumab/" | relative_url }}) - è­‰æ“šç­‰ç´š L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Etanerceptè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/etanercept/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_etanercept,
  title = {Etanerceptè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/etanercept/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
